Biotech entity
funding is the sole category represented across all 1 tracked stories. Orthopoxviruses is most often covered alongside Anthropic, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Orthopoxviruses, all published on September 11, 2026.
Last mentioned: 1d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
funding is the sole category represented across all 1 tracked stories. Orthopoxviruses is most often covered alongside Anthropic, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Orthopoxviruses, all published on September 11, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Orthopoxviruses. Shared-story counts are live from our verified record — not editorial picks.
Biotech and pharma stakeholders should note that Anthropic flagged possible gain-of-function research on chikungunya, bird flu, orthopoxviruses, and toxins. The findings intensify dual-use research of concern debate and may affect grant funding and oversight for virology and synthetic biology.
Orthopoxviruses is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
